Bonstein Sara 4
4 · Xilio Therapeutics, Inc. · Filed Jun 12, 2026
Research Summary
AI-generated summary of this filing
Xilio (XLO) Director Sara Bonstein Receives Option Grant for 5,000 Shares
What Happened Sara Bonstein, a director of Xilio Therapeutics, was granted a derivative award on June 11, 2026 covering 5,000 shares. The Form 4 reports the transaction as an award/grant (code A) at $0.00, indicating no cash purchase; this is an option-style grant rather than an open-market trade.
Key Details
- Transaction date: June 11, 2026; Form 4 filed June 12, 2026 (timely filing).
- Grant: 5,000-share option award reported at $0.00 (derivative).
- Vesting: The option vests 100% on the earlier of (i) June 11, 2027 or (ii) the issuer's next annual meeting of stockholders, subject to continued service. (Footnote from filing.)
- Shares owned after transaction: Not specified in the supplied filing details.
- No indication of a 10b5-1 plan, cashless exercise, tax withholding, or late filing in the provided information.
Context This filing documents a common form of director compensation (an option grant) rather than a market purchase or sale. The $0.00 reporting reflects that it is an award/option grant; exercise price and any future sales would be reported in subsequent filings if executed.
Insider Transaction Report
Form 4
Bonstein Sara
Director
Transactions
- Award
Stock Option (right to buy)
[F1]2026-06-11+5,000→ 5,000 totalExercise: $7.99Exp: 2036-06-10→ Common Stock (5,000 underlying)
Footnotes (1)
- [F1]The option was granted on June 11, 2026 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2027 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date.
Signature
/s/ Christopher Frankenfield, Attorney-in-Fact|2026-06-12